key: cord-0800509-d9avzdhe
authors: Di Castelnuovo, Dr. Augusto; Costanzo, Simona; Gialluisi, Alessandro; Iacoviello, Licia; de Gaetano, Giovanni
title: Hydroxichloroquine for COVID-19 infection: do we have a final word after one year?
date: 2021-10-26
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2021.10.026
sha: adf1e6539c22b49ee09eab9b0d9ab537ce939b13
doc_id: 800509
cord_uid: d9avzdhe

The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encouraged. However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤400 mg/day) deserves to be tested in large, well designed randomised clinical trials.

after one year? Di Furthermore, HCQ was not effective as a prophylaxis agent against SARS-CoV-2 infection, as it did not reduce clinical worsening, severe adverse events or all-cause mortality (8, 9) .

However, our findings from 27 cohort studies, including those of the CORIST collaboration, remain intriguing:

indeed, 8 studies reported a statistically significant association of HCQ use with lower mortality (relative risk ratio in the range 0.07 to 0.70), 8 studies found that HCQ use was associated with a non-statistically significant reduced relative risk of mortality (range 0.62 to 0.99) and 11 cohorts reported a positive, nonstatistically significant association with death (range 1.04 to 1.67). No study found a positive, statistically significant association of HCQ with increased mortality (3). These results prompted us to further investigate the reason(s) of the apparent discrepancy between findings from observational and interventional studies.

Using the same CORIST dataset, including more than 4,000 COVID-19 hospitalized patients, we tried to disentangle the possible association of HCQ with mortality through an unsupervised machine learning analysis (10, 11) . Using hierarchical clustering, we could identify two clusters of COVID-19 patients based on their socio-demographic and clinical characteristics: one, including younger patients with lower circulating inflammation levels and better renal function, and the other composed of generally older and more co-morbid subjects, more prevalently men and smokers. Interestingly, HCQ appeared to be associated with reduced mortality only in the low (hazard ratio 0.46, 95%CI: 0.39 to 0.54) but not in the high-risk cluster (hazard ratio 0.89, 95%CI: 0.65 to 1.22; P for difference P<0.001), suggesting a selective beneficial effect of HCQ in low risk COVID-19 patients (11) . This was in line with the findings of the IDENTIFY study, a multicentre US clinical trial (12) ; in that study, HCQ treatment was associated with higher survival in the treated harm, especially in those patients that were predicted to benefit most, based on a supervised machine learning algorithm applied to their characteristics. Among these, creatinine levela marker of renal functionwas one of the most important features in predicting the response to HCQ, in line with the CORIST study (4, 10) .

Together, these two independent lines of evidence suggest that patient subtyping and classification may represent a key to clearly define the actual efficacy of HQC treatment.

Another point of discussion is the notable discrepancy in HCQ dosage reported so far in observational vs RCT studies: the reduced mortality associated with HCQ use was actually confined in cohort studies that y ≤400 m (overall relative risk 0.69; 95%CI: 0.57 to 0.85), whereas it was null in studies in which a dose >400 mg/day was used (overall relative risk 1.05; 95%CI: 0.73 to 1.53; P=0.050 for difference)

(3). Notably, 5 over 11 RCTs used high doses of HCQ, including the large SOLIDARITY (5) and RECOVERY (6) studies, which both used 800 mg/day. The HCQ use was associated with an average 15% lower mortality in the 6 RCTs which used ≤400 m /day of HCQ, but a 10% higher mortality in the 5 RCTs which used higher doses (3). Though not statistically significant, this discrepant effect of lower and higher doses of HCQ warrants further consideration.

Evidence from RCTs is of fundamental importance for the assessment of clinical guidance; but a lesson from the HCQ use in COVID-19 patients is that findings from observational studies performed in real life conditions should be taken into consideration as they may help disentangling complex clinical and pharmacological scenarios.

The results presently available from RCTs and their meta-analysis indicate that HCQ is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of HCQ in COVID-19 patients cannot at present be encouraged. However, the hypothesis that HCQ might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤400 mg/day) deserves to be tested in large, well designed randomised clinical trials. More in general, a personalized medicine approach needs to be adopted in future RCTs.

Effects of chloroquine on viral infections: an old drug against today's diseases?

The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?

Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis

Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis

Updates on hydroxychloroquine in prevention and treatment of COVID-19

Common cardiovascular risk factors and inhospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering

Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial